Clinical Trial Detail

NCT ID NCT02467361
Title A Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Cancers
Recruitment Completed
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Boston Biomedical, Inc
Indications

Advanced Solid Tumor

Therapies

Nivolumab

Pembrolizumab

Ipilimumab

Napabucasin

Age Groups: adult

No variant requirements are available.